Canaccord lowered the firm’s price target on Teladoc (TDOC) to $12 from $14 and keeps a Buy rating on the shares. The firm said they posted a respectable quarter, highlighted by the announcement of the acquisition of UpLift, a virtual mental health provider with more than 1,500 clinicians with in-network coverage for over 100 million lives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Growth Potential Bolstered by Strategic Acquisition and Strong Performance
- Teladoc Health: Hold Rating Amid Strategic Acquisition and Segment Uncertainties
- Teladoc’s Strategic Moves and Financial Outlook: Hold Rating Amid Growth Potential and Margin Pressures
- Teladoc Health Reports Q1 2025 Financial Results
- Teladoc’s Transitional Phase: Hold Rating Amidst Slower Growth and Strategic Adjustments